Advertisement

Treatment of refractory hepatic encephalopathy induced by spontaneous portosystemic shunt: Selective splenic vein embolization versus shunt embolization

Published:September 26, 2022DOI:https://doi.org/10.1016/j.dld.2022.08.041

      Abstract

      Background and aims

      Spontaneous portosystemic shunt (SPSS) can cause refractory hepatic encephalopathy (HE) in cirrhotic patients. The embolization of the shunt (ES) can resolve the HE, while the selective embolization of the splenic vein (SESV) can treat splenorenal shunts related HE. The aim of this study was to compare the clinical outcomes of ES and SESV when applied for the treatment of SPSS-induced refractory HE in cirrhotic patients.

      Methods

      Patients with refractory HE who were treated with ES or SESV were retrospectively identified. The clinical outcomes were compared and analyzed.

      Results

      The 6-month mortality after the ES procedure was significantly higher than that after the SESV procedure. During the 6-month follow-up, both the white blood cell and the platelet counts were significantly lower after the ES procedure than after the SESV procedure. There was a significant increase in aspartate aminotransferase levels after ES. However, the albumin levels as well as the Child–Pugh score and grade were found to be significantly improved at 6 months after the undertaking of an SESV (as compared with baseline).

      Conclusion

      The 6-month mortality was improved after SESV (as compared with ES) in the treatment of SPSS-induced refractory HE. A prospective multicenter study for validation is warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rathi S.
        • Brocco S.
        • Formentin C.
        • et al.
        Spontaneous portosystemic shunts in cirrhosis: detection, implications, and clinical associations.
        Dig Liver Dis. 2020; https://doi.org/10.1016/j.dld.2020.11.020
        • Rajesh S.
        • Philips C.A.
        • Ahamed R.
        • et al.
        Friend or foe? Spontaneous portosystemic shunts in cirrhosis-current understanding and future prospects.
        Can J Gastroenterol Hepatol. 2021; 20218795115https://doi.org/10.1155/2021/8795115
        • Nardelli S.
        • Riggio O.
        • Turco L.
        • et al.
        Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis.
        Radiology. 2021; 299: 133-140https://doi.org/10.1148/radiol.2021203051
        • Dajti E.
        • Renzulli M.
        • Colecchia A.
        • et al.
        Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients.
        Dig Liver Dis. 2021; https://doi.org/10.1016/j.dld.2020.12.114
        • Montagnese S.
        • Russo F.P.
        • Amodio P.
        • et al.
        Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF).
        Dig Liver Dis. 2019; 51: 190-205https://doi.org/10.1016/j.dld.2018.11.035
        • Lynn A.M.
        • Singh S.
        • Congly S.E.
        • et al.
        Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy.
        Liver Transpl. 2016; 22: 723-731https://doi.org/10.1002/lt.24440
        • Laleman W.
        • Simon-Talero M.
        • Maleux G.
        • et al.
        Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.
        Hepatology. 2013; 57: 2448-2457https://doi.org/10.1002/hep.26314
      1. American Association for the Study of Liver D, European Association for the Study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.
        J Hepatol. 2014; 61: 642-659https://doi.org/10.1016/j.jhep.2014.05.042
        • Simon-Talero M.
        • Roccarina D.
        • Martinez J.
        • et al.
        Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis.
        Gastroenterology. 2018; 154 (e4): 1694-1705https://doi.org/10.1053/j.gastro.2018.01.028
        • Zamora C.A.
        • Sugimoto K.
        • Tsurusaki M.
        • et al.
        Portosplenic blood flow separation in a patient with portosystemic encephalopathy and a spontaneous splenorenal shunt.
        J Vasc Interv Radiol. 2004; 15: 875-879https://doi.org/10.1097/01.RVI.0000136984.47892.4C
        • Mezawa S.
        • Homma H.
        • Akiyama T.
        • et al.
        Selective embolization of the splenic vein in patients with hepatic encephalopathy and splenorenal shunt.
        J Vasc Interv Radiol. 2004; 15: 1475-1481https://doi.org/10.1097/01.RVI.0000141447.87966.D7
        • Arabi M.
        • Almat'hami A.
        • Qadri M.
        • et al.
        Shunt-preserving splenic vein embolization using a vascular plug for treatment of hepatic encephalopathy.
        J Vasc Interv Radiol. 2015; 26: 1416-1419https://doi.org/10.1016/j.jvir.2015.04.001
        • Khalilzadeh O.
        • Baerlocher M.O.
        • Shyn P.B.
        • et al.
        Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee.
        J Vasc Interv Radiol. 2017; 28 (e3): 1432-1437https://doi.org/10.1016/j.jvir.2017.06.019
        • Praktiknjo M.
        • Simon-Talero M.
        • Romer J.
        • et al.
        Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
        J Hepatol. 2020; 72: 1140-1150https://doi.org/10.1016/j.jhep.2019.12.021
      2. European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
        J Hepatol. 2010; 53: 397-417https://doi.org/10.1016/j.jhep.2010.05.004
        • Zhang H.
        • Xiao J.
        • Tu J.
        • et al.
        Prevention of variceal rebleeding in cirrhotic patients with spontaneous portosystemic shunts: transjugular intrahepatic portosystemic shunt versus endoscopic treatment.
        Eur J Gastroenterol Hepatol. 2021; 33: 752-761https://doi.org/10.1097/MEG.0000000000002079
        • Vidal-Gonzalez J.
        • Quiroga S.
        • Simon-Talero M.
        • et al.
        Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem.
        Therap Adv Gastroenterol. 2020; 131756284820961287https://doi.org/10.1177/1756284820961287
        • Nardelli S.
        • Riggio O.
        • Gioia S.
        • et al.
        Spontaneous porto-systemic shunts in liver cirrhosis: clinical and therapeutical aspects.
        World J Gastroenterol. 2020; 26: 1726-1732https://doi.org/10.3748/wjg.v26.i15.1726
        • Maruyama H.
        • Kondo T.
        • Kiyono S.
        • et al.
        Influence of splenorenal shunt on long-term outcomes in cirrhosis.
        Scand J Gastroenterol. 2015; 50: 593-600https://doi.org/10.3109/00365521.2014.1003401
        • Ikegami T.
        • Shirabe K.
        • Nakagawara H.
        • et al.
        Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation.
        Transplantation. 2013; 95: 1270-1277https://doi.org/10.1097/TP.0b013e318288cadc
        • He C.
        • Lv Y.
        • Wang Z.
        • et al.
        Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis.
        Dig Liver Dis. 2018; 50: 1315-1323https://doi.org/10.1016/j.dld.2018.05.022
        • Gomez Gavara C.
        • Bhangui P.
        • Salloum C.
        • et al.
        Ligation versus no ligation of spontaneous portosystemic shunts during liver transplantation: audit of a prospective series of 66 consecutive patients.
        Liver Transpl. 2018; 24: 505-515https://doi.org/10.1002/lt.24999
        • Franzoni Lde C.
        • de Carvalho F.C.
        • Garzon R.G.
        • et al.
        Embolization of splenorenal shunt associated to portal vein thrombosis and hepatic encephalopathy.
        World J Gastroenterol. 2014; 20: 15910-15915https://doi.org/10.3748/wjg.v20.i42.15910
        • Naeshiro N.
        • Kakizawa H.
        • Aikata H.
        • et al.
        Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: long-term outcomes in 14 patients.
        Hepatol Res. 2014; 44: 740-749https://doi.org/10.1111/hepr.12181